-
Oct 24, 2024 | 
medscape.com | Ursula Matulonis |Akila N. Viswanathan
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Ursula A. Matulonis, MD: Hello. I'm Dr Ursula Matulonis. Welcome to season 1 of the Medscape InDiscussion Endometrial Cancer podcast series. Today, we'll discuss radiation oncology and its role in the treatment of endometrial cancer. Let me introduce my guest, Dr Akila Viswanathan.
-
Aug 27, 2024 | 
medscape.com | Ursula Matulonis |Bhavana Pothuri
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Ursula A. Matulonis, MD: I'm Dr Ursula Matulonis. Welcome to season 1 of the Medscape InDiscussion: Endometrial Cancer podcast series. Today we'll discuss health disparities in the diagnosis and treatment of endometrial cancer. First, let me introduce my esteemed guest, Dr Bhavana Pothuri.
-
Jul 24, 2024 | 
medscape.com | Ursula Matulonis |Joyce Liu
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Ursula A. Matulonis, MD: I'm Dr Ursula Matulonis. Welcome to season 1 of the Medscape InDiscussion Endometrial Cancer podcast series. Today, we'll discuss what's new in targeted therapy for endometrial cancer. I'd like to first introduce my wonderful guest, Dr Joyce Liu.
-
May 7, 2024 | 
oncologynewscentral.com | Leah Lawrence |Youssef Rddad |Rabiya Tuma |Ursula Matulonis
-
Mar 20, 2024 | 
obroncology.com | Ursula Matulonis
Editor’s Note: This interview has been updated to more accurately reflect the characteristics of patients included in the RUBY clinical trial. Findings from immunotherapy trials in endometrial cancer presented at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer are “very much practice-changing,” says Ursula A. Matulonis, MD, chief of the division of gynecologic oncology at the Dana-Farber Cancer Institute in Boston.
-
Aug 10, 2023 | 
onclive.com | Ritu Salani |Ursula Matulonis |Bhavana Pothuri |Matthew Powell |Shannon N. Westin
Transcript:Ritu Salani, MD, MBA: Before we close, I want to ask each of you: I don’t know if we can predict 6 months from now, but where do you see the management of endometrial cancer in the next several years? Bhavana Pothuri, MD: We’ve already changed the way we look at endometrial cancer. We’ve gone to a molecular paradigm, with 4 subtypes. We’re a little behind in the United States compared with Europe. We need to start by doing molecular testing on all patients when they’re diagnosed.
-
Aug 10, 2023 | 
onclive.com | Ritu Salani |Ursula Matulonis |Bhavana Pothuri |Matthew Powell |Shannon N. Westin
Transcript:Ritu Salani, MD, MBA: The other complexity is that several other abstracts presented at this meeting looked at I/O [immuno-oncology] combinations, mostly checkpoint inhibitors. There was adalimumab-axitinib, which is presented in the mismatch repair [MMR]–proficient population, in recurrent or persistent endometrial cancer. There’s apatinib-camrelizumab. There’s cediranib-olaparib, olaparib-durvalumab, or cediranib-durvalumab in women with recurrent persistent ovarian cancer.
-
Aug 3, 2023 | 
onclive.com | Ritu Salani |Ursula Matulonis |Bhavana Pothuri |Matthew Powell |Shannon N. Westin
Transcript:Ritu Salani, MD, MBA: I want to touch briefly on lenvatinib-pembrolizumab, presented in KEYNOTE-775. We got final updates. Tell us your takeaways, because that changed the game for recurrent endometrial cancer. How do you think these new studies are going to affect that? I’ll start with you, Ursula. Ursula A.
-
Aug 3, 2023 | 
onclive.com | Ritu Salani |Ursula Matulonis |Bhavana Pothuri |Matthew Powell |Shannon N. Westin
Transcript:Ritu Salani, MD, MBA: I want to highlight a couple of abstracts that were presented. Bhavana, I’m going to start with you. [The phase 2 PHAEDRA trial looked at the] impact of mismatch repair deficiency and other molecular markers on clinical outcomes using durvalumab [and] a PD-L1 inhibitor in advanced endometrial cancer. What are your thoughts on this study?
-
Jul 27, 2023 | 
onclive.com | Ritu Salani |Ursula Matulonis |Bhavana Pothuri |Matthew Powell |Shannon N. Westin
Transcript:Ritu Salani, MD, MBA: Before we open this up to the panel, Bhavana, do you mind sharing a little about NRG-GY018? It was presented earlier this year as well. Highlight some of the differences between RUBY and the GY018 study. Bhavana Pothuri, MD: GY018 was presented by Dr Ramez Eskander at SGO [Society of Gynecologic Oncology Annual Meeting on Women’s Cancer]. This trial looked at the addition of pembrolizumab vs placebo to the standard chemotherapy backbone.
